RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics, Inc. announced today the 2009 Talecris New Trials Support (Talents) grant recipients. The Talents program, entering its fourth year, aims to advance basic and clinical research addressing the use of intravenous immunoglobulin (IGIV) in immunological, hematological, and neurological indications. The grants support either a one- or two-year research period and include funding for salary, overheads, and direct costs. Talecris produces and markets Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified), a leading IGIV therapy.
